Opaleye Management Inc., an investment manager that holds roughly 10% of SANUWAVE Health, Inc. (NASDAQ: SNWV), reported a series of sales in the company’s common stock totaling $336,982. The transactions took place between April 17 and April 21, 2026, with executed prices spanning $20.4611 to $20.5025 per share.
On April 17, Opaleye Management indirectly sold 11,267 shares held by Opaleye, L.P., and an additional 5,000 shares belonging to a separately managed account. Those disposals were carried out at a weighted average price of $20.4611 per share. The April 17 sales were part of multiple trades that day with individual prices ranging from $20.17 to $21.00.
Additional selling occurred on April 21, when Opaleye, L.P. indirectly sold 202 shares at $20.5025 per share. After the April transactions were recorded, Opaleye, L.P. reported ownership of 954,798 shares and the managed account reported ownership of 10,000 shares.
Opaleye Management serves as the investment manager for Opaleye, L.P. and as portfolio manager for the separately managed account, and the firm may be considered to beneficially own the reported securities. The company disclaims beneficial ownership of those shares except to the extent of its pecuniary interest. The Form 4 documenting these trades was made public on April 21, 2026.
The insider sales come while SANUWAVE’s shares trade below the transaction prices. The stock is currently quoted at $19.36, a decline from the prices at which Opaleye sold. According to InvestingPro data, the share price achieved a 10.6% return over the past week, and the stock exhibits elevated volatility with a beta of 1.51. Analysts retained a bullish stance on SANUWAVE, issuing price targets that range from $40 to $47.
Separately, SANUWAVE Health announced preliminary revenue results for the first quarter of 2026 between $9.6 million and $9.7 million. That top-line range represents a year-over-year increase of roughly 3% to 4%, which the company indicated is in line with prior guidance. SANUWAVE had reported record fourth-quarter 2025 revenue of $13.4 million, a 30% increase from the year before.
Despite the company’s recent revenue growth, the stock slipped in premarket trading after the Q4 results were released. The filings, revenue updates and share movement arrive amid commentary that investors are weighing possible strategic adjustments and broader industry challenges, factors that the company said have been elevating concern among market participants. Nonetheless, the preliminary Q1 figures continue to signal growth in SANUWAVE’s advanced wound care business.
Investors seeking more detailed analysis can access the comprehensive Pro Research Report available on InvestingPro for SANUWAVE and more than 1,400 other U.S. equities.